Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marshall Baek"'
Autor:
Christopher L. Bowlus, Bertus Eksteen, Angela C. Cheung, Douglas Thorburn, Cynthia A. Moylan, Paul J. Pockros, Lisa M. Forman, Alejandro Dorenbaum, Gideon M. Hirschfield, Ciara Kennedy, Thomas Jaecklin, Andrew McKibben, Elaine Chien, Marshall Baek, Pamela Vig, Cynthia Levy
Publikováno v:
Hepatology communications, vol 7, iss 6
BackgroundPrimary sclerosing cholangitis (PSC) is frequently associated with pruritus, which significantly impairs quality of life. Maralixibat is a selective ileal bile acid transporter (IBAT) inhibitor that lowers circulating bile acid (BA) levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785029c6b7ea0928b2edb7d0f5c56219
https://escholarship.org/uc/item/01g79818
https://escholarship.org/uc/item/01g79818
Autor:
Zhongqing He, Shringi Sharma, Joseph Ware, Helena Edlund, Helen Wei, Núria Buil-Bruna, Marshall Baek, Helen Tomkinson, Karthick Vishwanathan, Miné de Kock, Rakesh K. Raman, Huan Liu, Priti Patel
Publikováno v:
British Journal of Clinical Pharmacology. 88:2284-2296
Aims Examine relationships between the systemic exposure of acalabrutinib, a highly selective, next-generation Bruton tyrosine kinase inhibitor, and its active metabolite (ACP-5862) vs. efficacy and safety responses in patients with B-cell malignanci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d661a62dde63d808a29a323a3d8a1f34
https://doi.org/10.1111/bcp.15087
https://doi.org/10.1111/bcp.15087
Autor:
Nataliya Kuptsova-Clarkson, Jeff P. Sharman, Peter Hillmen, Clare Sun, Marshall Baek, Deborah M. Stephens, Tamara Lezhava, Paolo Ghia, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Javid Moslehi, Wojciech Jurczak, Richard R. Furman, Jennifer R. Brown, John C. Byrd
Publikováno v:
Blood. 136:52-54
Background: Bruton tyrosine kinase (BTK) inhibitors are effective treatments for B-cell malignancies, but an increased incidence of cardiovascular (CV) toxicities has been observed with ibrutinib. Acalabrutinib (acala) is a next-generation, potent, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::070fe7bbb7affd9e274d760d552e134c
https://doi.org/10.1182/blood-2020-134797
https://doi.org/10.1182/blood-2020-134797
Autor:
Raquel Izumi, Simon Rule, Jeff P. Sharman, Richard R. Furman, John M. Pagel, Susan O'Brien, Priti Patel, John C. Byrd, Beth Christian, Tamara Lezhava, Peter Hillmen, Marshall Baek, Ahmed Hamdy, Jennifer R. Brown, Clare Sun, Martin J.S. Dyer, Michael Wang, Roger G. Owen, Deborah M. Stephens, Nataliya Chernyukhin, Wojciech Jurczak, Paolo Ghia, Matthew Streetly
Publikováno v:
Leukemia. 35(11)
Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor. To characterize acalabrutinib tolerability, we pooled safety data from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3658df61f206c8845f463f15fa1a2e4
https://pubmed.ncbi.nlm.nih.gov/33907299
https://pubmed.ncbi.nlm.nih.gov/33907299
Autor:
Marshall Baek, Ming Yin, Nidal Al-Huniti, Zhongqing He, Shringi Sharma, Helena Edlund, Miné de Kock, Joseph A. Ware, Rakesh K. Raman, Karthick Vishwanathan, Huan Liu
Publikováno v:
Cancer Research. 80:3023-3023
Background: Acalabrutinib is a selective BTK inhibitor approved for the treatment of Mantle Cell Lymphoma. Relationship between plasma exposures to acalabrutinib and ACP-5862 versus clinical efficacy and safety were evaluated in subjects with B-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53268b5bbb32ccade4f674139b2aa942
https://doi.org/10.1158/1538-7445.am2020-3023
https://doi.org/10.1158/1538-7445.am2020-3023
Autor:
Clare Sun, Beth Christian, Roger G. Owen, Marshall Baek, Simon Rule, Deborah M. Stephens, John M. Pagel, John C. Byrd, Jeff P. Sharman, Martin J.S. Dyer, Richard R. Furman, Jennifer R. Brown, Michael Wang, Peter Hillmen, Susan O'Brien, Liat Schwartz-Sagi, Paolo Ghia, Wojciech Jurczak, Matthew Streetly, Priti Patel
Publikováno v:
Journal of Clinical Oncology. 38:8064-8064
8064 Background: Acala is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved in the US for patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and previously treated mantle cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34774fca0a10a86e9f973ca367be5dd6
https://doi.org/10.1200/jco.2020.38.15_suppl.8064
https://doi.org/10.1200/jco.2020.38.15_suppl.8064
Publikováno v:
American Journal of Preventive Medicine. 47:375-381
Background Type II diabetes and its complications can sometimes be prevented, if identified and treated early. One fifth of diabetics in the U.S. remain undiagnosed. Commonly used screening guidelines are inconsistent. Purpose To examine the optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26c4226147875d90f625856efb339407
https://doi.org/10.1016/j.amepre.2014.05.012
https://doi.org/10.1016/j.amepre.2014.05.012
Autor:
Powell O Jose, Kristin M Azar, Jennifer Kang, Marshall Baek, Latha P Palaniappan, Anita Sathe, Donna Malhotra, Jeannette Kotrys, Vijaya Deo, Shraddha Patel, Ashish Mathur, Cesar Molina
Publikováno v:
Circulation. 127
Background: Health coaching programs, delivered by trained non-medical and medical personnel, and focused on diet and lifestyle counseling, have proven beneficial in both primary and secondary prevention of cardiovascular disease. These coaching prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::177170e7f895773bf0e1958bb98843fa
https://doi.org/10.1161/circ.127.suppl_12.ap238
https://doi.org/10.1161/circ.127.suppl_12.ap238
Autor:
Stephen P. Fortmann, Marshall Baek, Beinan Zhao, Sukyung Chung, Powell Jose, Latha Palaniappan
Publikováno v:
Journal of the American College of Cardiology. 61(10)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2013f2c04d32dcb259ee80ee6d67ae45